Next Article in Journal
The Impact of the COVID-19 Emergency on Life Activities and Delivery of Healthcare Services in the Elderly Population
Next Article in Special Issue
Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
Previous Article in Journal
Impact of COVID-19 on Eye Care in Spain during the First Phase of the Pandemic
Previous Article in Special Issue
The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients
Review

BCMA in Multiple Myeloma—A Promising Key to Therapy

1
Division of Internal Medicine, University Hospital of Zurich, 8091 Zurich, Switzerland
2
Faculty of Medicine, University of Basel, 4031 Basel, Switzerland
3
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece
*
Author to whom correspondence should be addressed.
Academic Editor: Krzysztof Giannopoulos
J. Clin. Med. 2021, 10(18), 4088; https://doi.org/10.3390/jcm10184088
Received: 11 August 2021 / Revised: 6 September 2021 / Accepted: 7 September 2021 / Published: 10 September 2021
Despite the discoveries of numerous agents including next generation proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, multiple myeloma (MM) remains an incurable disease. The field of myeloma treatment in refractory or relapsed patients after standard therapy entered a new era due to the B-cell maturation antigen (BMCA) targeted approach. BCMA is a member of the tumor necrosis factor receptor family with high expression in mature B-lymphocytes and plasma cells. Given the understanding of BCMA mechanism of action in MM, BCMA plays a promising role as a therapeutic target. Several clinical trials are underway to evolve the current BCMA targeted treatment concept such as antibody-drug conjugates (ADCs), bispecific T cell engagers (BITEs) and chimeric antigen receptor (CAR) T cell therapy. Current results of representative BCMA trials may close the gap of the unmet clinical need to further improve the outcome of heavily pretreated MM patients with the potency to change the paradigm in newly diagnosed and refractory MM. This comprehensive review will give an update on various BMCA targeted treatment modalities (ADCs, BITEs, CAR T cell therapy) and its existing results on efficacy and safety from preclinical and clinical trials. View Full-Text
Keywords: BCMA; multiple myeloma; antibody; conjugated; BiTE; ADC; CAR T cell; immunotherapy BCMA; multiple myeloma; antibody; conjugated; BiTE; ADC; CAR T cell; immunotherapy
MDPI and ACS Style

Kleber, M.; Ntanasis-Stathopoulos, I.; Terpos, E. BCMA in Multiple Myeloma—A Promising Key to Therapy. J. Clin. Med. 2021, 10, 4088. https://doi.org/10.3390/jcm10184088

AMA Style

Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in Multiple Myeloma—A Promising Key to Therapy. Journal of Clinical Medicine. 2021; 10(18):4088. https://doi.org/10.3390/jcm10184088

Chicago/Turabian Style

Kleber, Martina, Ioannis Ntanasis-Stathopoulos, and Evangelos Terpos. 2021. "BCMA in Multiple Myeloma—A Promising Key to Therapy" Journal of Clinical Medicine 10, no. 18: 4088. https://doi.org/10.3390/jcm10184088

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop